iVexSol Inc.

iVexSol Inc. is a biotechnology company that specializes in advanced vector production technologies, focusing on innovative solutions for cell and gene therapies to enhance the efficiency of lentiviral vector production. iVexSol Inc. was founded in 2019 and is headquartered in Worcester, US.

The company develops technologies for vector production, particularly in the cell and gene therapy sectors. CEO Rodney Rietze leads the firm, which has undergone three significant funding rounds, with the latest being a Series A round in January 2023 that raised USD 23. 8 mn from investors including Asahi Kasei Medical Co. , Ltd.

and Bristol-Myers Squibb Company. The company has achieved a total amount raised of USD 23. 8 mn to date, valuing it at USD 60. 104 mn.

iVexSol specializes in advanced vector production technologies, particularly for cell and gene therapies. Its core offerings include a next-generation stable lentiviral vector production platform and intelligent manufacturing solutions, aimed at overcoming challenges in lentiviral vector production. Utilizing serum-free, suspension host cells and engineered plasmids, iVexSol efficiently produces high-quality, high-titer vectors that support clients throughout clinical development stages, from preclinical trials to late-phase commercialization. The company serves a global clientele, including biopharmaceutical companies and research institutions across North America, Europe, and Asia.

iVexSol generates revenue through a B2B model, forming partnerships with biopharmaceutical companies and research institutions for vector production services. Revenue streams include contract agreements for on-demand vector production, where clients order based on their clinical development needs. Although specific pricing details are not disclosed, revenue is derived from both one-time production runs and ongoing support agreements. The company's offerings, particularly its Intelligent Manufacturing solutions, are integral to its revenue generation, addressing the growing demand for gene and cell therapies.

Following the most recent Series A funding of USD 23. 8 mn on January 26, 2023, iVexSol plans to enhance its technical teams and infrastructure to support the production of stable lentiviral vector producer cell lines. The company aims to expand its market presence, particularly targeting new geographical regions in Europe and Asia by late 2024, while continuing to innovate its product offerings to meet the increasing demand in the biopharmaceutical sector.